Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 324 participants.
Also called NCT07173712
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 324 participants
- Sponsor
- Yanbing Li
- Registry
-
NCT07173712
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07173712. Randomized; no masking; primary purpose treatment. Start 2026-03-15 (anticipated); primary completion 2027-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- CSII
- Intervention (Drug)
- Insulin glargine /lixisenatide Fixed Ratio Combination
- Intervention (Drug)
- Insulin Degludec and Insulin Aspart Injection
- Intervention (Drug)
- Insulin Glargine (HOE901 - U300)
- Intervention (Drug)
- Metformin
- Lead sponsor
- Yanbing Li
Record details
- Record id
cardio:ct-nct07173712- Content hash
fb4900523ac912fd8f033ce54334af0119279d232ddf6ba419497a908b8ec96d